Carisma Therapeutics Collaborates With Moderna To Announce Their Nomination Of First In Vivo CAR-M Development Candidate For Hepatocellular Carcinoma; Nomination Triggers A $2M Milestone Payment To Carisma
Portfolio Pulse from Benzinga Newsdesk
Carisma Therapeutics Inc. (NASDAQ:CARM) and Moderna, Inc. (NASDAQ:MRNA) have announced the nomination of their first in vivo CAR-M development candidate targeting Glypican-3 for the treatment of solid tumors, including hepatocellular carcinoma. This nomination triggers a $2 million milestone payment to Carisma.

June 27, 2024 | 8:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Carisma Therapeutics has nominated its first in vivo CAR-M development candidate under its collaboration with Moderna, targeting Glypican-3 for treating solid tumors. This nomination triggers a $2 million milestone payment to Carisma.
The nomination of the development candidate and the associated $2 million milestone payment are positive developments for Carisma, likely boosting investor confidence and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Moderna collaborates with Carisma Therapeutics to nominate their first in vivo CAR-M development candidate targeting Glypican-3 for treating solid tumors, including hepatocellular carcinoma.
Moderna's collaboration with Carisma and the nomination of a new development candidate highlight its ongoing innovation in cancer treatment, which could positively impact its stock price.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70